Caeli Vascular

Executive Summary

Caeli Vascular is a private medical device company founded in 2019 and based in San Diego, California. The company is developing a catheter-based thrombectomy system designed to safely and completely remove large-volume deep vein thrombosis (DVT). Current treatment options for severe DVT are limited, leaving patients at high risk of pulmonary embolism and long-term complications. Caeli's technology aims to address this unmet need by providing a more effective and safer solution for clot removal. The company is in the early stages of development, with no disclosed funding or valuation, but its focused approach on a significant clinical problem positions it as a potential disruptor in the cardiovascular device space. Given the early stage, Caeli Vascular faces typical challenges of device development, including regulatory hurdles, clinical validation, and capital requirements. However, the large addressable market for DVT treatment and the clear clinical need for improved thrombectomy devices support a moderate conviction in the company's potential. Key catalysts over the next 12-18 months would include initiation of first-in-human studies, securing FDA breakthrough device designation, or forming strategic partnerships. The company's progress will depend on successful execution of its development plan and ability to attract necessary funding.

Upcoming Catalysts (preview)

• Q3 2026First-in-Human Clinical Trial Initiation40% success
• Q4 2026FDA Breakthrough Device Designation60% success
• Q1 2027Series A Funding Round Completion50% success